- Understand currently available medication for the treatment of sickle cell
- Learning Objective 2:Understand the role Endari has in the treatment of sickle cell
- Learning Objective 3:Understand the short comings of Endari
- Can icosapent ethyl reduce CV Risk in patients with hypertriglyceridemia?
- Learning Objective 2:Does icosapent ehthyl have additive benefit to statins in patients with DM or CV ds and hypertriglyceridemia.
- Learning Objective 3:Critical review of randomized trial
Monday, March 4, 2019 - 12:00pm to 1:00pm
Add to calendar:
UCMC Room L431
Chicago, IL 60637
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation